Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Mavorixafor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6X4 PHARMS

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2036-12-22

    MAVORIXAFOR

    US Patent Number : 11219621

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 218709

    Patent Use Code : U-3932

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-12-22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2036-12-22

    MAVORIXAFOR

    US Patent Number : 10610527

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 218709

    Patent Use Code : U-3932

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-12-22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2038-12-11

    MAVORIXAFOR

    US Patent Number : 11045461

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 218709

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-12-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2036-12-14

    MAVORIXAFOR

    US Patent Number : 10953003

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 218709

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-12-14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2038-12-11

    MAVORIXAFOR

    US Patent Number : 12115156

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 218709

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-12-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    X4 PHARMS

    MAVORIXAFOR

    arrow
    The Generic Rx Session
    Not Confirmed

    X4 PHARMS

    Country
    arrow
    The Generic Rx Session
    Not Confirmed

    Patent Expiration Date : 2038-12-11

    MAVORIXAFOR

    US Patent Number : 10548889

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 218709

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-12-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF